



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/728,173		
		Filing Date	December 1, 2000		
		First Named Inventor	Keisuke Kuida		
		Art Unit	1632		
Examiner Name	D. Crouch				
Sheet	1	of	1	Attorney Docket Number	VPI/98-104 CIP CON US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.C./	A1	US-2003-0105046	06-05-2003	Yuan et al.	
	A2	US-2003-0198949	10-23-2003	Goldmakher et al.	
	A3	US-2003-0207262	10-06-2003	Goldmakher et al.	
	A4	US-2005-0089984	04-28-2005	Dixit et al.	
	A5	US-6,010,878	01-04-2000	Dixit et al.	
	A6	US-6,218,511	04-17-2001	Goldmakher et al.	
	A7	US-6,294,169	09-25-2001	Dixit et al.	
	A8	US-6,605,426	08-12-2003	Goldmakher et al.	
/D.C./	A9	US-6,890,721	05-10-2005	Dixit et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/D.C./	B1	EP-0808904	11-26-1997	Smithkline Beecham Corp et al.		
↓	B2	EP-0842665	05-20-1998	Smithkline Beecham Corp		
	B3	WO-97/46663	12-11-1997	Smithkline Beecham Corp et al.		
	B4	WO-98/57664	12-23-1998	Yuan Junying et al.		
/D.C./	B5	WO-99/60171	11-25-1999	Apoptosis Technology Inc		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.C./	C1	Villa et al., "Capases and caspase inhibitors," TIBS Trends in Biochemical Sciences, 22(10):388-393, (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Deborah Crouch/	Date Considered	06/28/2007
--------------------	------------------	-----------------	------------

Please type a plus sign (+) inside this box: →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	69/428,173
				Filing Date	December 1, 2000
				First Named Inventor	Keisuke Kuida et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	VPI/98-104 CIP CON

[illegible][illegible]

Examiner Signature		Date Considered	3.14.05
-----------------------	---	--------------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	01/728,143
		Filing Date	December 1, 2000
		First Named Inventor	Keisuke Kuida et al.,
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	VPI/98-104 CIP CON	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	B1	DUAN H. et al., "ICE-LAP6 a novel member of the ICE/Ced-3 gene family."; J. Bio. Chem; Vol. 6, No. 28; 7/12/96 Pgs 16720-16724	
	B2	HAKEM R. et al., "Differential requirement for caspase 9.." CELL; Vo. 94, No. 3; 8/7/98; PP 339-352	
	B3	KUIDA K. et al., "Reduced apoptosis and cytochrom c-mediated caspase.."; CELL, Vol. 9, No. 3, 8/7/98; PP 325-337	
	B4	KUIDA K. et al., "Decreased apoptosis in the brain and .." NATURE, Vol. 384, No. 6607; 11/28/96; PP 368-372	
	B5	LI Peng, et al., "Cytochrom c and dATP-dependent formation of .."; CELL, Vo. 91, No. 4.; 11/14/97; PP 479-489	
	B6	SOENGAS M., et al., "Apaf-1 and caspase-9 in p53 dependent ..."; SCIENCE, Vo. 284, No. 5411; 2/4/1999, PP 156-159.	

Examiner Signature	<i>[Signature]</i>	Date Considered	3/4/05
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.